Genetically determined variability in acetylation and oxidation. Therapeutic implications.
about
Respiratory diseases in minorities of the United StatesUnravelling the Secrets of Mycobacterial Cidality through the Lens of AntisenseShould we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression.Acute and chronic arsenic toxicity.Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians.A comparison of drug protein binding and alpha 1-acid glycoprotein concentration in Chinese and Caucasians.Variability in the elimination of mianserin in elderly patients.Mephenytoin and sparteine oxidation: genetic polymorphisms in DenmarkEvidence for polymorphic oxidation of sparteine in Japanese subjectsEstimating the clearance of amylobarbitone from a single plasma measurementInfluence of age, sex and body weight on the dapsone acetylation phenotype.Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.N-acetylation phenotyping with dapsone in a mainland Chinese population.N-acetylation polymorphism of dapsone in a Japanese populationSparteine oxidation is practically abolished in quinidine-treated patients.Zonisamide in pediatric epilepsy: review of the Japanese experience.Pharmacogenetics of the arylamine N-acetyltransferases.Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies.Genetic aspects of drug disposition and therapeutics.Pharmacogenetics and anesthesiologists.Immunogenetics of drug-induced skin blistering disorders. Part II: synthesis.Pharmacogenetics in reproductive and perinatal medicine.Review of knowledge for rational design and identification of anti-tubercular compounds.Distribution of xenobiotic metabolising enzyme genotypes in different Tunisian populations.Practical clinical pharmacology: drug handling and responseGenetic factors in toxicology: implications for toxicological screening.Basic concepts in drug metabolism: Part II.A simple method for determining acetylator phenotype using isoniazidDifferential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients.Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.Acetylator phenotype in relation to age and gender in the Baltimore Longitudinal Study of Aging.The safety of clozapine in the elderly.
P2860
Q23911640-7D7B54AE-A0DA-4B5F-BB76-2E853AB2357EQ28551800-27588403-F8B7-47A0-BD0B-D1B8090675A5Q33770163-18061588-296F-4DC4-84BC-1AFF1637F51DQ33924148-E68AD75D-0BFF-4A8C-B59E-237001B09968Q34219547-EB408130-D5B7-452B-8830-BB7260AFEA15Q34347670-250194B0-C02C-4811-ACE5-6807B8660723Q34358499-EB007091-423F-4475-9E4C-6A8B01A7642BQ34397048-CDADE62C-ED2A-453C-85D4-1958950E5885Q34397680-3B0ED1DB-2C77-4C8A-BCF3-C7AD1C0F73EDQ34416359-2D293601-F386-47E4-9640-4B76071F009EQ34416506-9B6282EE-7E34-40F8-A1D2-C43B9C90F6C5Q34416569-81439E10-1BC5-4F12-8FCD-912E187B5343Q34417415-AB17A38F-8AFE-4D19-A9D4-C0B3ABBF9C07Q34418319-D06F7EA6-CB96-41C6-A915-ED81DACD8782Q34421140-51E97037-E341-4A49-B944-7784F81C6C20Q34447888-FEAFED2B-A44C-4B50-9070-55101FD82177Q34599818-73D7078F-D44C-476A-AE31-2000058A960BQ34624647-16F7C1BE-6B44-4F75-AB5D-DF6F1AEC9753Q36084984-16B0AE8F-A6C0-4FC1-93A4-94306E93FD69Q36244452-79ECA6B0-4034-46CC-AD9C-7D58CD76F1BDQ36317007-E4E0ACCE-9766-44DD-8DDF-60DD349790AFQ37486715-0F40CBA7-3BFB-4F1D-923C-8CAA08929067Q37657531-E3D23854-8C13-4855-B8F2-593EADD122F7Q38088324-7708AA8C-6AFB-448E-8F98-02FD3B6A838DQ39097942-97D392A5-A43F-4C7D-88DF-6907B5D5FF67Q39602431-A45055F6-4B21-4482-8742-0F4B18B4AFA4Q39673571-944DCD13-81DB-4494-BEA4-5A2A3ED9F12AQ39679818-92F1D98E-155A-49EE-B23E-F21B214409AEQ42095737-B7D8741F-9691-41CF-9DF5-51DA359EEB20Q43222657-92723F48-7F10-4653-89A5-DC84B883F72BQ44380081-B9DD9786-A122-475F-92ED-F668E81BF526Q46621913-67283847-60D1-46DB-874E-102D17CE7320Q50970497-4DDBC70F-82BA-45DE-B8B4-5AEFC907D31CQ51886953-786E94CA-6A83-47D4-A88F-15126DAE7972
P2860
Genetically determined variability in acetylation and oxidation. Therapeutic implications.
description
1985 nî lūn-bûn
@nan
1985 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Genetically determined variabi ...... ion. Therapeutic implications.
@ast
Genetically determined variabi ...... ion. Therapeutic implications.
@en
Genetically determined variabi ...... ion. Therapeutic implications.
@nl
type
label
Genetically determined variabi ...... ion. Therapeutic implications.
@ast
Genetically determined variabi ...... ion. Therapeutic implications.
@en
Genetically determined variabi ...... ion. Therapeutic implications.
@nl
prefLabel
Genetically determined variabi ...... ion. Therapeutic implications.
@ast
Genetically determined variabi ...... ion. Therapeutic implications.
@en
Genetically determined variabi ...... ion. Therapeutic implications.
@nl
P1433
P1476
Genetically determined variabi ...... ion. Therapeutic implications.
@en
P2093
P304
P356
10.2165/00003495-198529040-00003
P577
1985-04-01T00:00:00Z
P6179
1036326624